Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

SPOTLIGHT: BIGS GETTING BIGGER

Each week, we report instances where the money junky hedge funds, private equity groups and the already big companies swallow another piece of the global economy. Here are some more examples of what the BIGS have been gobbling up and how the Bigs keep getting bigger and the rich keep getting richer…
AFTER RECORD REVENUES, PFIZER IS ON THE HUNT
Sale of Pfizer’s COVID vaccines will garner $32 billion this year, the company forecasts, and sales of its COVID-curing pill will add another $22 billion, bringing the pharma giant’s income for the year to about $100 billion, it said.
Last year’s sales were $76 million for the pill and $36.8 billion for the vaccine, the highest annual sales ever for any pharma product, according to The Wall Street Journal.
Pfizer plans to use its cash windfall to continue buying up companies developing  drugs in Pfizer’s areas of focus, including immunology, cancer, and rare diseases. 
Pfizer has bought a slate of competitors recently, including several making mRNA vaccines and its $6.7-billion purchase of Arena Pharmaceuticals in December, which we reported in “Pfizer Buys Arena Pharmaceutical for $6.7 Billion” (21 Dec 2021).
Arena makes drugs to treat inflammatory bowel conditions.
Pfizer expects to make new buys that will add $25 billion to its annual revenue by 2030, the WSJ reported. 
APOLLO CLOSING DEAL TO BUY WORLDLINE’S POINT-OF-SALE BUSINESS
Apollo Global Management is finalizing negotiations to buy Worldline SA’s point-of-sale terminal business for about €2 billion, or roughly $2.3 billion, The Wall Street Journal reported.
The buyout specialist will take possession of a hardware and software network that enables consumers to pay for purchases with their smartphones or plastic cards, a trend that has grown dramatically during the COVID era.
The digital payments business has become especially lucrative for private equity firms.
In a recent transaction, takeover firm Hellman & Friedman sold Nets Group, a Scandinavian payments business, to Italy’s Nexi SpA for €6 billion; in 2018, Francisco Partners led a group that bought Verifone for $2.6 billion.

Worldline has been revamping its focus to concentrate on cloud-based payments that generate recurring revenue.
It acquired competitor Ingenico for €7.8 billion last fall, confirming its position as a leading European payments company.